Literature DB >> 7285481

Ceforanide kinetics in renal insufficiency.

S S Hawkins, R H Alford, W J Stone, R D Smyth, M Pfeffer.   

Abstract

Ceforanide (500 mg) was infused intravenously over 30 min into six normal subjects, 10 nondialysis patients with renal insufficiency, and six hemodialysis patients. Dialysis patients received two ceforanide infusions, one immediately before dialysis and another during an interdialysis period. Sequential plasma samples over 24 to 72 hr were assayed for ceforanide. Peak ceforanide levels (mean = 69 +/- 12 micrograms/ml) and volumes of distribution did not vary with creatinine clearance (Clcr, ml/min/1.73 m2) and both plasma clearance and renal clearance decreased linearly as Clcr decreased. Mean nonrenal clearance (4.6 +/- 1.8 ml/min/1.73 m2) did not vary with Clcr. Mean half-life was 3 hr in the normal subjects, increasing to approximately 25 hr in patients with severe renal insufficiency. Hemodialysis resulted in a removal of approximately 21% of the dose of ceforanide. Dosing recommendations for patients with renal insufficiency are provided.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285481     DOI: 10.1038/clpt.1981.190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 4.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.